Abstract Objectives: To assess the utility of capsaicin test in the differential diagnosis of non-productive causes of chronic cough and to examine the effects of treatment on this reflex. Participants: 86 healthy volunteers and 101patients with chronic cough: asthma (n: 54), gastroesophageal reflux (n: 35) and post-nasal drip syndrome (n:12). Design: Prospective intervention trial. Spirometry, bronchoprovocation test with histamine (PC 20 ), and cough challenge with ascending concentrations of capsaicin (0.49^500 mM) were initially performed in all subjects. Patients were treated for 3 months according to the origin of the cough.Concentrations that elicited two (C 2 ) and five or more coughs (C 5 ) were determined before and after treatment. Results: In healthy subjects, cough sensitivity to capsaicin was not influenced by gender or smoking status; however, women with chronic cough were more sensitive to cough challenge than men. C 2 and C 5 were significantly lower in patients with asthma or gastroesophageal reflux than in post-nasal drip syndrome. No significant correlation was observed between the capsaicin cough threshold and PC 20 . Cough sensitivity did not improve significantly in most patients with asthma or gastroesophageal reflux despite adequate medical treatment during 3 months. Discriminative value of capsaicin testto differentiate healthy subjects from patients with asthma or reflux was poor. Conclusions: Cough sensitivity to inhaled capsaicin is a safe and reproducible tool in the study of chronic cough. However, its usefulness for the management and differential diagnosis is limited. r
INTRODUCTION
Cough is a common symptom in respiratory disease. It has been estimated that 10^40% of o⁄ce visits per year in general practice are due to this symptom (1) . Asthma, gastroesophageal re£ux, and post-nasal drip syndrome, alone or in combination, account for the majority of cases of persistent cough in patients who are referred to pulmonary specialists (2, 3) . In these cases, cough usually results from the stimulation of sensory nerves in the airway with activation of irritant receptors (myelinated rapidly adapting stretch receptors) or C-¢ber endings in the larynx or tracheobronchial tree (4) . It has been suggested that chronic airway irritation, irrespective of the original cause (in£ammation or aspiration), may lead to the development of a sensory hyperresponsiveness of cough receptors (5, 6) . According to this hypothesis, the mechanism by which gastroesophageal re£ux, asthma or post-nasal drip syndrome induces cough may be similar: enhanced sensitization of airway sensory nerves.
Capsaicin, the active ingredient of red pepper, is a commonly used cough stimulant in the study of cough reactivity and for the evaluation of antitussive agents in humans (7^9). It has been shown to produce cough mainly by stimulating C-¢ber endings and also by stimulating some rapidly adapting receptors with myelinated ¢bers (10) . Although di¡erent studies(11^13)have demonstrated that capsaicin is safe to use and produces a dose-dependent and reproducible cough response in a variety of conditions, there are scarce studies reporting reference values of cough threshold to inhaled capsaicin in healthy subjects. Moreover, usefulness of capsaicin challenge in the diagnostic algorithm of chronic cough has not been determined (14) .
The present study was designed with the following purposes: (1) to determine our normal range of cough threshold to inhaled capsaicin, (2) to assess the sensitivity of capsaicin test in the di¡erential diagnosis of nonproductive persistent cough, and (3) to examine the effects of treatment of the underlying condition on cough sensitivity.
MATERIALS AND METHODS

Study subjects
Patients referred to our Service of Pneumology for study and treatment of unexplained cough of more than 4 weeks duration were included in the study. None of them had been previously diagnosed of any chronic respiratory disease or were taking bronchodilators and/or inhaled corticosteroids. Additional exclusion criteria were the presence of acute respiratory infections during the previous 4 weeks. Active smokers (patients who smoked in the last month) and patients receiving angiotensin-converting enzyme inhibitors or drugs that may in£uence airway reactivity or lower esophageal sphincter tone were also excluded. In order to obtain our own reference values, a group of healthy individuals free from respiratory disease (normal physical examination and lung function) participated in the study. The study was approved by the institutional review board, and written informed consent was obtained from all subjects after the purpose of the diagnostic evaluation and the capsaicin challenge test had been explained.
Study design
Patients with chronic cough underwent a thorough diagnostic evaluation (14) that consisted of medical history (cough characteristics, respiratory, and digestive symptoms), physical examination, chest radiography, and pulmonary function testing including spirometry and bronchodilator test (Fig.1) .When a diagnosis was initially suspected, a speci¢c diagnostic test was indicated (¢rst step in the algorithm). In this sense, sinus X-ray ¢lms, histamine challenge, or 24 -h esophageal monitoring were performed on an individual basis. If the diagnosis was established by the tests, speci¢c treatment was instituted. One or more ¢nal diagnosis were only established after successful treatment response to adequate 3-month therapy.(Final step of the algorithm). When initial clinical ¢ndings did not suggest a speci¢c cause, a bronchoprovocation histamine challenge was ¢rst ordered. If it was negative, a 24 -h pH-monitoring was indicated. Unsuccessful treatment at 1 month was followed by additional tests in the order which is indicated in the algorithm and treatment response was newly reevaluated.
Asthma was diagnosed in the presence of symptoms of episodic wheezing, cough, and shortness of breath with positive challenge tests (PC 20 histamine o8 mg/dl) or increased forced expiratory volume in 1s (FEV 1 ) after bronchodilator inhalation (([postFEV 1 ÀpreFEV 1 ]/predicted FEV 1 )412% and 200 ml). Treatment included inhaled steroids (£uticasone 500 mg/day) and salbutamol as needed. Gastroesophageal re£ux was diagnosed when the percentage of time with a pH below 4 was 48% for the upright, 44% for recumbent, and 45% for the total time. Patients with gastroesophageal re£ux were treated with lifestyle changes and omeprazole (40 mg/day).
Post-nasal drip syndrome was suspected when patients complained of having something dripping into the throat, nasal discharge, mucus drainage in the posterior oropharynx or hoarseness. Laryngitis was diagnosed by indirect laryngoscopy taking into consideration the presence of mucosal integrity and erythema. Patients with post-nasal drip syndrome were treated with nasal steroids (£uticasone 250 mg/day) antihistamines (loratadine 10 mg/day), and topical decongestants (d-isoephredine).
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Good response
Gastroesophageal reflux
Histamine challenge test was performed according to the method described by Cockcroft et al. (15) . Histamine doses were inhaled from a Hudson Up Draft II nebulizer (output 0.13 7 0.002 ml/min) operated by an electric compressor (Pari TherapiegerÌt Privat). FEV 1 before and after each inhalation was measured on a dry wedge spirometer (Vitalograph, Vitalograph Ltd., U.K.) and bronchial hyperresponsiveness was expressed as the histamine provocation concentration producing a 20% fall in the FEV 1 (PC 20 FEV 1 ).
Gastroesophageal re£ux was measured by 24 -h esophageal and gastric pH monitoring using antimony pH electrodes (Monocrystant 91-0011, Synectics Medical, Stockholm, Sweden) connected with a dual-channel pHmeter (Digitrapper Mark III, Synectics). Probes were introduced transnasally and the distal electrode were located 5 cm above the upper limit of manometrically de¢ned lower esophageal sphincter. The proximal electrode was placed immediately under the upper esophageal sphincter. Recorded data were evaluated with an ambulatory pH software package (Gastrosoft,WI, U.S.A.). Patients were instructed to lead their normal lives. Esophagoscopy was also performed in patients with gastroesophageal re£ux or severe digestive symptoms to exclude the presence of esophagitis.
Following the diagnostic protocol and before speci¢c treatment was indicated, patients and healthy individuals underwent the capsaicin challenge. Maximum FEV 1 and FVC, ( Vitalograph LTD, Buckingham, U.K.) were determined before and after the capsaicin challenge to investigate the bronchoconstrictor e¡ect of capsaicin. Cough intensity was measured using a visual decimal scale (01 0, where 0: no cough and 10: maximal cough) initially and after treatment. In order to evaluate the e¡ects of treatment, capsaicin cough challenge was repeated after a 3-month treatment period. Likewise, reproducibility of the test was assessed in healthy subjects at 3 months.
Capsaicin Challenge
Capsaicin (Sigma Chemical, Poole, U.K.) was prepared by dissolving 30.5 mg of the substance in1ml of 96% ethanol and 1ml of polyoxyethylenesorbitan monooleate 80 (Tween 80) and then dissolved in 8 ml physiologic saline solution to make a stock solution of10 À2 M.This solution was further diluted with saline solution to make serial doubling concentrations ranging from 0.49 to 500 mM. Fresh dilutions were prepared each day of testing. Aerosol was delivered through a breath-activated nebulizer controlled by a dosimeter (Optineb Air Liquid), set to nebulize for 0.9 s. The challenge was performed by single-breath inhalation of doses increasing from 0.49 to 500 mM. Subjects were asked to inhale once deeply over 2 s at 2-min intervals. The number of coughs during the ¢rst 30 s after each dose was counted.The challenge was terminated when the subject cough ¢ve or more times (C 5 ) or the maximal dose of capsaicin was attained. In subjects who did not have cough, a value of C 5 of 500 mM was assumed. The concentration of capsaicin inducing two coughs (C 2 ) was also recorded. Subjects were unaware that cough was the speci¢c point of research interest.
Statistical analysis
Capsaicin log C 2 and log C 5 values were expressed as geometric means and 95% con¢dence intervals (CIs). To test reproducibility, an intraclass correlation coe⁄cient was calculated. In assessing the relationship of cough threshold to age, gender, histamine PC 20 , FEV 1 , and duration of cough, a Pearson's product^moment correlation analysis was performed. Di¡erences in clinical variables in each group were assessed using the Chi-squared test. In patients with gastroesophageal re£ux, the association between cough threshold and re£ux severity or the presence of esophagitis and laryngitis was also investigated. The di¡erences in mean values for log C 2 and log C 5 for the patient groups were evaluated by analysis of variance. A value of Po0.05 was considered to be signi¢-cant. Changes in capsaicin concentrations after treatment were expressed in doubling concentrations [(log capsaicin after treatment À log capsaicin before treatment)/log 2) and patients divided into responders (doubling concentrations 41.2 or the cuto¡ point for the 95th percentile in healthy subjects) and non-responders. Di¡erences between responders and non-responders were evaluated by t test for independent samples. Finally, the ability of the capsaicin challenge test in the diagnosis of chronic cough was assessed by calculating the sensitivity, speci¢city, false-positive rate, and falsenegative rate for each inhaled concentration value. The best cut-o¡ point that separates healthy and the di¡er-ent groups was obtained with a graphical ROC curve, constructed by plotting sensitivity against false-positive rate for each value. Area under curve of the di¡erent ROC curves were compared. Other cuto¡ values were obtained corresponding to the values with greatest speci¢city.
RESULTS
A total of 113 patients (41 men and 72 women) were initially studied. In 12 of the 113 cases, a de¢nitive diagnosis was not established and they were excluded from the analysis. Baseline characteristics of patients in the study are shown in Table 1 . The underlying causes of chronic cough included asthma in 54 patients, gastroesophageal re£ux in 35 (in association with bronchial hyperrespon-siveness in 12), and post-nasal drip syndrome in 12. Intergroup di¡erences in relation to demographic, clinical characteristics, and duration of cough were not signi¢cant. As expected, the frequency of digestive symptoms and shortness of breath was signi¢cantly di¡erent in patients with gastroesophageal re£ux or asthma group.
Eighty-six healthy volunteers (36 men and 50 women) participated in the study to obtain the reference values. Results of spirometry and capsaicin challenge of this group are shown inTable 2.There were no di¡erences between capsaicin cough thresholds between smokers and non-smokers. Likewise they were not in£uenced by gender. However, cough sensitivity was related with age (r = À0.27, Po0.05).
Reproducibility of the capsaicin challenge performed in this group was high (intraclass correlation coe⁄cient: 0.75 (95% CI 0.53^0.87) and 0.88 (95% CI 0.76^0.94) for C 2 and C 5 values, respectively].
There were not any changes in spirometric values following capsaicin challenge.
Results of capsaicin cough challenge in subjects with chronic cough (Table 2) revealed that patients with asthma or gastroesophageal re£ux showed signi¢cantly lower pre-treatment cough threshold concentrations than healthy subjects or patients with post-nasal drip syndrome. In patients with chronic cough, cough threshold was signi¢cantly lower in women than in men and there was a statistically signi¢cant inverse relationship between cough sensitivity and age (r = À0.33, Po0.05). Capsaicin cough sensitivity was signi¢cantly related to previous duration of cough, especially in asthmatic patients (r = À0.43, Po0.01). As a whole, no relationship was found between histamine PC 20 and cough sensitivity in patients with chronic cough. This absence of correlation was also con¢rmed in the asthmatic group.
In patients with gastroesophageal re£ux, log C 2 and log C 5 values were not in£uenced by the presence of laryngitis or esophagitis. Capsaicin sensitivity was also not signi¢cantly di¡erent between patients with proximal or distal re£ux.
In all patients, cough decreased progressively and almost disappeared after 90 days of treatment. However, in the majority of patients with asthma or gastroesophageal re£ux, cough re£ex sensitivity did not vary after 3 months of treatment as shown in Fig. 2 . There were no di¡erences in demographic and clinical characteristics, duration of cough, and bronchial hyperresponsiveness between responders (n = 31) and non-responders (n = 70).
As indicated by the ROC curves (Fig. 3 ) the optimal cuto¡ point to di¡erentiate asthma patients from healthy subjects was 31 mM (sensitivity 94%, speci¢city 50%) and the optimal cuto¡ point to distinguish patients with gastroesophageal re£ux from healthy subjects was 15 mM (sensitivity 98%, speci¢city 66%). The area under the ROC curve was slightly higher in patients with gastroesophageal re£ux (0.88, SD = 0.41) than in patients with asthma (0.82, SD = 0.36). The lowest cuto¡ point in healthy subjects was 125 mM. Capsaicin threshold higher than this value showed a 100% speci¢city for excluding sensory hyperresponsiveness as the cause of cough.
DISCUSSION
We have demonstrated that testing cough sensitivity to inhaled capsaicin is a safe and reproducible tool in the study of non-productive chronic cough. However, its usefulness for the management and di¡erential diagnosis is limited.
Sensory hyperresponsiveness to capsaicin was only seen in patients with asthma or gastroesophageal re£ux. Patients with post-nasal drip syndrome were found to have normal sensitivity of the cough re£ex and, therefore, were di¡erent from the remaining patients with chronic cough.The absence of this response is important because it could serve to exclude this condition in clinical practice. Cough sensitivity, which was independent of bronchial hyperresponsiveness even in asthmatic patients, was only related to the duration of the symptom and gender. A heightened sensitivity of the cough re£ex to inhaled capsaicin in women compared with men was found.
Reference values in healthy subjects have not been clearly established due to the lack of standardization of assessment of cough sensitivity to inhaled capsaicin and the relatively small number of healthy subjects included in the di¡erent studies.C 2 and C 5 were arbitrarily chosen for comparison with international literature. Our mean C 2 and C 5 values of 32 (23^44) and 151 (125^186) mM, respectively, in normals are similar than ¢ndings reported by Choudry and Fuller (12) . In contrast to sex di¡erences reported by Fujimura et al. (16) and by Dicpinigaitis and Rauf (17) , cough threshold in our series was similar in males than in females. In the former studies, gender difference was a signi¢cant predictive factor for cough sensitivity in either age group. Likewise, gender in£uence has been documented in other modalities of evoked cough (citric acid, tartaric acid). Reproducibility of the test in 28 healthy subjects who took part in both the ¢rst and second experiments (3 months apart) was good, with a high intraclass correlation coe⁄cient, i.e., equal to or less than 1 as expressed in doubling concentrations. Reproducible cough responses to capsaicin challenge in both adults and children have been previously found by others (11, 16, 18) . Little has been reported on the usefulness of capsaicin test in studies of the cough re£ex in disease. Choudry and Fuller 12 found that patients with non-productive cough had a higher sensitivity of the cough re£ex (log C 5 :1.16) than patients with productive cough (log C 5 :1.54) or healthy subjects (log C 5 :1.78). Increased cough sensitivity was also found in patients given angiotensin-converting enzyme inhibitors, in patients with previous viral infections, and in patients with gastroesophageal re£ux. In the latter, tussive response to capsaicin was enhanced even in patients without cough (13, 19) .The reason for this response is not clear. Any parameter of esophageal function or re£ux is associated with the reduced cough threshold. It has been hypothesized that long-lasting exposure of the mucosa to gastric juices could produce enhancement of the cough re£ex.
Airway in£ammation in patients with asthma is probably the cause of the increased sensitivity to capsaicin. However, mechanisms underlying cough production are not always related to those determining bronchial reactivity. In the present study, sensory hyperresponsiveness to capsaicin in patients with asthma was independent of bronchial hyperresponsiveness to histamine.
In healthy individuals, several studies have not found di¡erences between smokers and non-smokers (12) . These ¢ndings are in agreement with the present results. Cough is a frequent symptom in smokers and patients with COPD. Previous studies showed that patients with chronic bronchitis had normal responses to capsaicin (20) ; however, Doherty et al. (21) have demonstrated that cough re£ex is also increased in patients with COPD and it is independent of air£ow limitation.Upper respiratory infection may cause cough as a result of increased sensitivity of capsaicin-sensitivity a¡erent airway nerves without a¡ecting airway calibre or responsiveness. O'Connell et al. (22) have shown that in subjects with dry cough C 5 was lower during infection than both baseline and recovery.
No previous data have been reported in relation to the diagnostic accuracy of capsaicin cough challenge in terms of sensitivity and speci¢city. With a cuto¡ point of 15 mM, the predictive capacity of the test for di¡erentiat-ing patients with chronic cough from those with gastroesophageal re£ux was higher than for di¡erentiating patients with chronic cough from asthmatics or patients with post-nasal drip syndrome. In case of using results of capsaicin challenge in diagnostic algorithms, they would seem particularly useful to exclude the diagnosis of postnasal drip syndrome in a patient with chronic cough.
On the other hand, studies of capsaicin sensitivity after successful treatment of cough are limited. In patients with gastroesophageal re£ux, some authors (19) have shown that omeprazol improves not only digestive symptoms but also the cough threshold to capsaicin.This improvement was signi¢cant after 5 days in most of the patients. In the present study, cough sensitivity remains increased despite favorable clinical response to treatment both in asthma and gastroesophageal re£ux. The inclusion of patients without cough in the former study could explain some of the di¡erences. Likewise, several studies have documented that multiple causes may be present in the individual patient.This feature could modify the results of the capsaicin test.To avoid it, we choose only patients who responded successfully to speci¢c treatment.We prefer this stepping approach instead that every patient has had all examinations.The persistence of cough re£ex sensitivity may add a valuable objective parameter to continue with treatment until a normal sensitivity has been attained.
In summary, capsaicin challenge has a limited usefulness in the di¡erential diagnosis and management of diseases causing an increase in the sensitivity of cough re£ex.
